LIXT: חוב לטווח קצר להון עצמי Lixte Biotechnology Holdings Inc.

This Lixte Biotechnology (LIXT) price chart on the GURU.Markets platform reflects the asset's dynamics, with a current valuation of 0.07. The business relies on the development of protein phosphatase inhibitors, creating a critical dependency on the success of a single drug. Lixte Biotechnology develops anti-tumor agents in US centers utilizing enzyme blocking. However, a narrow development pipeline and high capital requirements increase the probability of delisting.

By outsourcing drug synthesis to external CDMO partners, Lixte Biotechnology (LIXT) minimizes capital expenditures on production. By analyzing the ratio of short-term loans to equity on GURU.Markets, an investor assesses the company's reliance on short-term liabilities relative to its capital, which helps identify the risk of cash flow gaps and confirm the asset's financial stability during clinical trial periods.